Noxap (Nitric Oxide)

Nitric Oxide, the active ingredient in Noxap, is a vasodilator presented as an inhalation gas for respiratory administration. It facilitates pulmonary vasodilation and is used in diagnostic imaging and certain vascular conditions.

GNH USA supplies Noxap as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Noxap, a nitric oxide donor, is employed in clinical settings that require pulmonary vasodilation or vascular imaging.

- Persistent pulmonary hypertension of the newborn (PPHN): improves oxygenation by lowering pulmonary vascular resistance. - Acute respiratory distress syndrome (ARDS): provides selective pulmonary vasodilation to enhance gas exchange. - Pulmonary hypertension during cardiac surgery: reduces right‑ventricular afterload and improves intra‑operative hemodynamics. - Vascular imaging: acts as a contrast agent to delineate pulmonary vessels during functional imaging studies.

Adverse reactions may occur with inhaled nitric oxide therapy.

Common Side Effects: - Hypotension: transient drop in systemic blood pressure. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Flushing of the skin. - Nausea or mild gastrointestinal discomfort. - Cough or throat irritation.

Serious or Rare Side Effects: - Methemoglobinemia: elevated methemoglobin levels impair oxygen delivery. - Rebound pulmonary hypertension on abrupt discontinuation. - Severe hypotension requiring intervention. - Bleeding complications, especially when combined with anticoagulants. - Infection risk if delivery system becomes contaminated. - Pulmonary edema in susceptible patients.

Careful monitoring and specific precautions are recommended when using Noxap.

- Blood pressure monitoring: observe for hypotension and adjust therapy as needed. - Methemoglobin assessment: regularly measure levels to detect methemoglobinemia. - Controlled environment: administer only in facilities equipped for inhaled gas delivery and scavenging. - Contraindications: avoid in patients with severe anemia or known hypersensitivity to nitric oxide. - Caution with phosphodiesterase inhibitors: increased risk of profound hypotension. - Store at ambient temperature: keep container sealed, protect from moisture and direct sunlight.

Nitric oxide can interact with several drug classes, requiring attention to avoid adverse events.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may cause severe systemic hypotension. - Inhaled anesthetics (e.g., nitrous oxide): additive vasodilatory effect increases hypotension risk. - Systemic vasodilators (e.g., nitroglycerin): can potentiate blood pressure lowering.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding tendency. - Hemoglobin‑modifying agents: may exacerbate methemoglobinemia. - Other nitric‑oxide donors: cumulative exposure can increase toxicity. - Sulfonamide antibiotics: potential to raise methemoglobin levels. - Bronchodilators: may alter distribution of inhaled gas and affect efficacy.